

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: IFT2/18 - Immunophenotypisation

Dead line: 22.10.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(253) CD 3+ T lymphocytes					99							99	92	93%
Samples and groups	[%]													
Sample A		65,4	2,3	3,5	99	CVP	65,4	0,56	7%	60,8	70	99	95	96%
(12) Beckman Coulter		65,9	2,2	3,4	57	0						57		
(88) Becton Dickinson		64,9	2,4	3,6	37	0						37		
(177) MINDRAY		65,3	2,1	3,2	5	0						5		
Sample B		68,3	1,6	2,4	99	CVP	68,3	0,40	7%	63,5	73,1	99	95	96%
(12) Beckman Coulter		68,9	1,3	1,9	57	0						57		
(88) Becton Dickinson		67,3	2,2	3,2	37	0						37		
(177) MINDRAY		67,8	1,1	1,6	5	0						5		
(254) CD 4+ T lymphocytes					99							99	93	94%
Samples and groups	[%]													
Sample A		44,4	2,3	5,1	99	CVP	44,4	0,56	10%	39,9	48,9	99	94	95%
(12) Beckman Coulter		44,9	2,0	4,6	57	0						57		
(88) Becton Dickinson		43,7	2,7	6,2	37	0						37		
(177) MINDRAY		44,9	2,0	4,4	5	0						5		
Sample B		52,4	1,5	2,8	99	CVP	52,4	0,36	10%	47,1	57,7	99	96	97%
(12) Beckman Coulter		52,9	1,1	2,2	57	0						57		
(88) Becton Dickinson		51,4	2,2	4,3	37	0						37		
(177) MINDRAY		52,5	0,44	0,85	5	0						5		
(255) CD 8+ T lymphocytes					99							99	92	93%
Samples and groups	[%]													
Sample A		16,0	1,1	7,0	99	CVP	16	0,28	17%	13,2	18,8	99	95	96%
(12) Beckman Coulter		15,6	1,1	7,1	56	0						56		
(88) Becton Dickinson		16,5	1,0	6,2	38	0						38		
(177) MINDRAY		16,5	0,25	1,5	5	0						5		
Sample B		13,4	0,75	5,6	99	CVP	13,4	0,19	17%	11,1	15,7	99	94	95%
(12) Beckman Coulter		13,2	0,72	5,4	56	0						56		
(88) Becton Dickinson		13,6	1,0	7,6	38	0						38		
(177) MINDRAY		13,4	0,38	2,8	5	0						5		
(256) B lymphocytes					99							99	97	98%
Samples and groups	[%]													
Sample A		17,6	1,2	7,0	99	CVP	17,6	0,31	30%	12,3	22,9	99	99	100%
(12) Beckman Coulter		17,2	1,2	7,1	57	0						57		
(88) Becton Dickinson		18,1	1,4	7,8	37	0						37		
(177) MINDRAY		17,7	1,0	5,9	5	0						5		
Sample B		13,5	0,85	6,3	99	CVP	13,5	0,21	30%	9,45	17,6	99	97	98%
(12) Beckman Coulter		13,3	0,83	6,2	57	0						57		
(88) Becton Dickinson		13,9	0,93	6,7	37	0						37		
(177) MINDRAY		13,5	0,15	1,1	5	0						5		
(257) NK cells					99							99	91	92%
Samples and groups	[%]													
Sample A		14,5	1,8	13	99	CVP	14,5	0,45	26%	10,7	18,3	99	95	96%
(12) Beckman Coulter		14,4	1,7	12	57	0						57		
(88) Becton Dickinson		14,6	2,1	14	37	0						37		
(177) MINDRAY		14,6	0,68	4,7	5	0						5		
Sample B		16,3	1,6	9,5	99	CVP	16,3	0,38	26%	12	20,6	99	92	93%
(12) Beckman Coulter		16,0	1,3	8,3	57	0						57		
(88) Becton Dickinson		16,9	2,0	12	37	1						37		
(177) MINDRAY		17,2	0,28	1,6	5	0						5		

st_kn_p

End of report

Printed: 01.11.2018